Donanemab for early Alzheimer's: a real-world study
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early symptoms of Alzheimer's, like mild memory or thinking problems, but can still do daily activities on your own.
- You have a brain scan, spinal tap, or blood test (within the last year) that shows signs of Alzheimer's disease.
- You have a friend or family member who can talk to the study team by phone every 6 months about how you're doing.
- You don't have a history of stroke that left you unable to bathe, dress, or walk on your own.
- You don't have any other serious illness (like cancer or severe mental illness) that would make it hard to finish the study.
- You are not currently in another experimental treatment study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
This trial tests if an investigational drug called donanemab can lower amyloid plaques in the brain to slow Alzheimer's disease in adults with Down syndrome. Participants must be 35–50, have elevated brain amyloid, and not have dementia yet.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.